AGM-1470 Property

Melting point:

90-93°C

alpha 

D24 -46.6° (c = 0.44 in CHCl3)

Density 

1.26±0.1 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

DMSO: >15mg/mL

form 

White to light yellow solid

pka

7.19±0.46(Predicted)

color 

White to Pale Yellow Waxy

Stability:

Hygroscopic

Safety

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26

WGK Germany 

2

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

AGM-1470 Chemical Properties,Usage,Production

Description

TNP-470 is a synthetic analog of fumagillin that inhibits angiogenesis. It irreversibly inactivates methionine aminopeptidase-2 (MetAP2; IC₅₀ = 2 μM), blocking endothelial cell proliferation in vitro and angiogenesis in vivo. It is without effect on MetAP1. TNP-470 has therapeutic potential in cancer and microsporidiosis.

Uses

TNP-470 is a synthetic analog of fumagillin that inhibits angiogenesis. It irreversibly inactivates methionine aminopeptidase-2 (MetAP2; IC50 = 2 μM), blocking endothelial cell proliferation in vitro and angiogenesis in vivo. It is without effect on MetAP1. TNP-470 has therapeutic potential in cancer and microsporidiosis.

Uses

TNP-470 is a synthetic analog of Fumagillin (F862650); a compound isolated from the fungus Aspergillus fumigatus. Fumagillin is an antimicrobial agent used in the treatment of microsporidiosis and shows promise as both an anti-infective and antiangiogenic agent.

Definition

ChEBI: A carbamate ester that is fumagillol in which the hydroxy group has been converted to the corresponding N-(chloroacetyl)carbamate derivative.

General Description

TNP-470 is a synthetic analogue of fumagillin. It is a natural product of Aspergillus fumigatus. TNP-470 serves as an angiogenesis inhibitor.

Biological Activity

Analog of Fumagillin ((2E,4E,6E,8E)-Mono[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2 -methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5] oct-6-yl] 2,4,6,8-decatetraenedioic acid ester) that displays potent antiangiogenic activity in vitro and in vivo . Inhibits methionine aminopeptidase type II (MetAP2).

Biochem/physiol Actions

TNP-470 is a methionine aminopeptidase-2 (MetAP-2) inhibitor, selective for MetAP-2 over MetAP11. TNP-470 is an antiangiogenic.

in vitro

antitumor activity of tnp-470 was evaluated in eight human cultured cell lines derived from choriocarcinoma; ovarian cancer; tyk and nakajima; and uterine endometrial cancer. results showed that after 7-day culture with tnp-470, in medium at the concentration of 10 to 10-2 μg/ml, the inhibition of growth was observed in all of the eight cell lines. the half inhibitory concentration of choriocarcinoma cell lines was at an extremely low level compared to that of e uterine endometrial cancer and pithelial ovarian cancer [1].

in vivo

the anti-tumor effect of tnp-470 was studied using nude mice with tumors of gch-1(m), nuc-1, or nakajima cells. when the size of the transplanted tumor reached 100–200 mm3, 3, 10, or 30 mg/kg of tnp-470 was injected every other day. it was found that the inhibitory effect of tnp-470 was obtained by the administration of 10 and 30 mg/kg in gch-1(m) and nuc-1 cells, respectively, while in nakajima cells there was no significant effect. in addition, in nude mice treated with 30 mg/kg of tnp-470, lung metastasis of gch-1(m) cells was greatly inhibited both in the number and the size of tumor nodules, suggesting that the capillary growth in the originally developed tumor was also reduced [1].

IC 50

2 μm

References

[1] t. yanase, m. tamura, k. rujita, et al. inhibitory effect of angiogenesis inhibitor tnp-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. cancer research 53(11), 2566-2570 (1993).
[2] c j logothetis et al. phase i trial of the angiogenesis inhibitor tnp-470 for progressive androgen-independent prostate cancer. clinical cancer research 7(5):1198-203.